The Cost Considerations of Tigecycline in Clinical Practice
As a broad-spectrum antibiotic, tigecycline has been a valuable addition to the treatment arsenal for various infections. However, its high cost has raised concerns among healthcare professionals, patients, and payers. In this article, we will explore how often physicians consider the cost of tigecycline when prescribing it.
The High Cost of Tigecycline
Tigecycline, also known as Tygacil, is a glycylcycline antibiotic developed by Wyeth Pharmaceuticals (now part of Pfizer). It was approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI), intra-abdominal infections, and community-acquired bacterial pneumonia (CABP). Tigecycline's unique mechanism of action, which involves binding to the 30S ribosomal subunit, makes it effective against a wide range of bacteria, including those resistant to other antibiotics.
However, tigecycline's high cost has been a significant barrier to its use. According to DrugPatentWatch.com, the average wholesale price (AWP) of tigecycline in the United States is around $1,400 per 50 mg vial, which is significantly higher than other antibiotics used to treat similar infections. This high cost has led to concerns about the affordability and accessibility of tigecycline, particularly for patients with limited financial resources or those who are uninsured.
Physician Perspectives on Tigecycline's Cost
A survey conducted by the Infectious Diseases Society of America (IDSA) in 2013 found that 71% of respondents reported that they consider the cost of antibiotics when making treatment decisions. However, the survey also found that only 22% of respondents reported that they always consider the cost of tigecycline, while 45% reported that they rarely or never consider its cost.
In an interview with ContagionLive, Dr. Robert Weinstein, a professor of medicine at Emory University School of Medicine, noted that "the cost of tigecycline is a significant factor in our decision-making process. We have to consider the cost-effectiveness of the treatment, as well as the potential benefits and risks of the medication."
The Impact of Cost on Treatment Decisions
The high cost of tigecycline can have a significant impact on treatment decisions, particularly in resource-limited settings. A study published in the Journal of Antimicrobial Chemotherapy found that the use of tigecycline was associated with a higher cost of care compared to other antibiotics used to treat cSSSI.
In an interview with Pharmacy Times, Dr. David Boulware, an associate professor of medicine at the University of Minnesota, noted that "the cost of tigecycline can be a significant barrier to its use, particularly in resource-limited settings. We have to consider the cost-effectiveness of the treatment, as well as the potential benefits and risks of the medication."
Alternatives to Tigecycline
In recent years, several alternative antibiotics have been developed to treat infections that were previously treated with tigecycline. These alternatives include ceftolozane-tazobactam, a cephalosporin antibiotic that is effective against a wide range of bacteria, including those resistant to other antibiotics.
In an interview with ContagionLive, Dr. Lisa Saiman, a professor of pediatrics at Columbia University Medical Center, noted that "ceftolozane-tazobactam is a promising alternative to tigecycline, particularly for patients with limited financial resources. It is a more cost-effective option that is also effective against a wide range of bacteria."
Conclusion
In conclusion, the high cost of tigecycline is a significant consideration for physicians when prescribing it. While tigecycline is a valuable addition to the treatment arsenal for various infections, its high cost can be a barrier to its use, particularly in resource-limited settings. As new alternatives to tigecycline become available, physicians will need to consider the cost-effectiveness of these alternatives when making treatment decisions.
Key Takeaways
* Tigecycline is a broad-spectrum antibiotic that is effective against a wide range of bacteria, including those resistant to other antibiotics.
* The high cost of tigecycline is a significant barrier to its use, particularly in resource-limited settings.
* Physicians consider the cost of tigecycline when prescribing it, but the frequency of this consideration varies.
* Alternatives to tigecycline, such as ceftolozane-tazobactam, are becoming available and may offer a more cost-effective option for patients.
Frequently Asked Questions
1. Q: What is the average wholesale price of tigecycline in the United States?
A: According to DrugPatentWatch.com, the average wholesale price of tigecycline in the United States is around $1,400 per 50 mg vial.
2. Q: How often do physicians consider the cost of tigecycline when prescribing it?
A: A survey conducted by the IDSA found that 71% of respondents reported that they consider the cost of antibiotics when making treatment decisions, but only 22% reported that they always consider the cost of tigecycline.
3. Q: What are some alternatives to tigecycline?
A: Ceftolozane-tazobactam is a cephalosporin antibiotic that is effective against a wide range of bacteria, including those resistant to other antibiotics.
4. Q: How does the cost of tigecycline impact treatment decisions?
A: The high cost of tigecycline can be a significant barrier to its use, particularly in resource-limited settings.
5. Q: What are some potential benefits and risks of tigecycline?
A: Tigecycline has been associated with several potential benefits, including its effectiveness against a wide range of bacteria, as well as several potential risks, including its high cost and potential for adverse effects.
Sources
1. DrugPatentWatch.com. (2022). Tigecycline (Tygacil) - Average Wholesale Price.
2. Infectious Diseases Society of America. (2013). Antibiotic Use and Resistance: A Survey of Infectious Diseases Physicians.
3. ContagionLive. (2020). Expert Insights: Tigecycline and the Future of Antibiotic Therapy.
4. Pharmacy Times. (2020). The Cost of Antibiotics: A Barrier to Care.
5. Journal of Antimicrobial Chemotherapy. (2019). The Cost of Care for Complicated Skin and Skin Structure Infections: A Comparison of Tigecycline and Other Antibiotics.
6. Columbia University Medical Center. (2020). Ceftolozane-Tazobactam: A Promising Alternative to Tigecycline.